Trump says Nvidia not allowed to sell advanced AI chips to China- 60 Minutes
NEW YORK - Intensity Therapeutics, Inc. (NASDAQ:INTS) announced Thursday that its Phase 1/2 clinical study results for INT230-6 in treating metastatic or refractory cancers have been published in eBioMedicine, a Lancet Discovery Science journal. The micro-cap biotech, currently valued at just $13.09 million, is trading at $0.27 per share as it advances its cancer treatment pipeline.
The study, led by researchers from the University of Southern California, showed that in heavily pretreated patients with over 20 different cancer types, intratumoral INT230-6 achieved a disease control rate of 75% and median overall survival of 11.9 months.
An exploratory analysis revealed that patients receiving INT230-6 doses treating more than 40% of their total tumor burden showed significantly better outcomes, with median overall survival of 18.7 months compared to 3.1 months for those receiving lower relative doses.
The treatment demonstrated favorable safety with no dose-limiting toxicities reported among the 64 monotherapy patients. Only seven patients experienced grade 3 adverse events (10.9%), with no grade 4 or 5 treatment-related events observed.
According to the published data, INT230-6 induced decreases in proliferating cancer cells in injected tumors and increases in activated T-cells in the tumor microenvironment. Approximately 20% of patients showed shrinkage in uninjected tumors, known as abscopal effects.
INT230-6 is designed for direct intratumoral injection and consists of two anti-cancer agents, cisplatin and vinblastine sulfate, combined with a diffusion enhancer molecule that helps the drugs disperse throughout tumors.
The company has initiated a Phase 3 study in soft tissue sarcoma and a Phase 2 study in collaboration with The Swiss Cancer Institute for patients with presurgical triple-negative breast cancer.
Intensity Therapeutics will host a webinar with the paper’s authors on Friday to discuss the results.
The information in this article is based on a company press release statement.
In other recent news, Intensity Therapeutics has reported several key developments. Brookline Capital Markets has upgraded the company’s stock rating from Hold to Buy, setting a price target of $3.00. This upgrade is attributed to positive outcomes in Intensity’s clinical trials and an improved financial position. The company has also announced that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, meeting the $2.5 million threshold. In contrast, Benchmark has lowered its price target for Intensity Therapeutics to $1.50, citing recent share dilution, although it maintains a Speculative Buy rating. These updates come on the heels of Intensity’s progress in the INVINCIBLE-4 Phase 2 trial for women with triple negative breast cancer. The trial evaluates the efficacy of INT230-6 when combined with standard care. These developments reflect the company’s ongoing efforts in clinical advancements and financial compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.